209 related articles for article (PubMed ID: 27168342)
1. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
[No Abstract] [Full Text] [Related]
2. Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.
Tuttle RM; Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):12-3. PubMed ID: 27168343
[No Abstract] [Full Text] [Related]
3. [Use of new molecules in the treatment of advanced thyroid cancer].
Galofré JC; Gómez-Sáez JM; Álvarez Escola C; Álvarez García E; Anda Apiñaniz E; Calleja A; Donnay S; Lucas-Martin A; Menéndez Torre E; Navarro González E; Pereg V; Pérez Corral B; Santamaría Sandi J; Riesco Eizaguirre G; Zafón Llopis C;
Endocrinol Nutr; 2011 Oct; 58(8):381-6. PubMed ID: 21924966
[No Abstract] [Full Text] [Related]
4. [New therapies in thyroid cancer].
López Mondéjar P; Galofré JC
Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
[No Abstract] [Full Text] [Related]
5. What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
Atkins MB
Clin Adv Hematol Oncol; 2016 Jun; 14(6):417-9. PubMed ID: 27379810
[No Abstract] [Full Text] [Related]
6. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
7. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
8. Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
Basu S; Kalshetty A
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1092-1094. PubMed ID: 28236023
[No Abstract] [Full Text] [Related]
9. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V; Carlomagno F; Li HY; Santoro M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
[TBL] [Abstract][Full Text] [Related]
12. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
13. Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.
Lalami Y; Awada A
Curr Opin Oncol; 2011 May; 23(3):235-40. PubMed ID: 21330922
[TBL] [Abstract][Full Text] [Related]
14. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib improves survival in refractory thyroid cancer.
Mayor S
Lancet Oncol; 2015 Mar; 16(3):e110. PubMed ID: 25683848
[No Abstract] [Full Text] [Related]
17. Update on multikinase inhibitor therapy for differentiated thyroid cancer.
Agrawal VR; Jodon G; Mushtaq R; Bowles DW
Drugs Today (Barc); 2018 Sep; 54(9):535-545. PubMed ID: 30303494
[TBL] [Abstract][Full Text] [Related]
18. Kinase inhibitors for refractory thyroid cancers.
Schlumberger M
Lancet Oncol; 2010 Oct; 11(10):912-3. PubMed ID: 20851683
[No Abstract] [Full Text] [Related]
19. New perspectives on the treatment of differentiated thyroid cancer.
Coelho SM; Carvalho DP; Vaisman M
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):612-24. PubMed ID: 17684624
[TBL] [Abstract][Full Text] [Related]
20. Evolving approaches to patients with advanced differentiated thyroid cancer.
Haugen BR; Sherman SI
Endocr Rev; 2013 Jun; 34(3):439-55. PubMed ID: 23575762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
